Q2 2013 GSK Results

GSK announces Q2 core EPS growth of 4% and dividend of 18p

Core EPS growth of 4% on sales growth of 2% (both CER)
Pharma & Vaccines +1%; US +5%; EMAP +2%; Europe flat; Japan -5%
Consumer Healthcare +2% (+5% excluding divestments)
3 major US approvals: Breo Ellipta for COPD, Tafinlar & Mekinist for metastatic melanoma
Q2 dividend of 18p (+6%)
Total share repurchases for 2013 to be £1-2bn
More details with CFO interview available in the quarterly results section of this website.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Link to the press release

See on www.gsk.com

From Pharmaceutical Industry digital vision


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s